Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors
US7008948B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 22, 2003 |
| Grant date | Mar 7, 2006 |
| Priority date | — |
| Expiry date | Jul 22, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.